New drug aims to shield vision during optic neuritis attacks

NCT ID NCT04762017

Completed Disease control Sponsor: Oculis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a new drug called OCS-05 in 36 people with acute optic neuritis, a condition that inflames the optic nerve and can cause vision loss. Participants received OCS-05 or a placebo alongside standard steroid treatment for five days. The main goal was to check safety, and researchers also measured changes in retinal thickness to see if the drug might protect eye health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCS-05 (given intravenously with corticosteroids)
What this could lead to: If successful, this could point toward a treatment that protects vision during optic neuritis attacks.
What could go wrong: This is a small, early-phase safety study with only 36 people. It is not designed to prove the drug works, and results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPTIC NEURITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

optic neuritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPTIC NEURITIS

Contacts and locations

Locations

CHU - Nice

Nice, 06000, France
CIC Neurosciences - La Pitié Salpêtrière

Paris, 75013, France
Foundation Rothschild

Paris, 75019, France
Hospices Civils de Lyon

Lyon, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.